Company Overview and News
New Zealand shares fell for a second day with Meridian Energy lower as the power company confronts dry conditions, and exporters Comvita and Fisher & Paykel Healthcare faced a stronger kiwi dollar.
RHCGF SPKKY EBOSY NZTCY SPK NZTCF RYM EBO SKT GNE AOTUF EBOSF SYKWF PPSHY RYHTY VTHPF SKKTY GNE MEZ GEL EBO
New Zealand shares fell for a seventh day. Rising US bond yields kept a lid on equity markets across Asia, weighing on growth-orientated stocks such as A2 Milk Co and Pushpay Holdings.
AIR FCREY ZNRGF NZTCF RYM ACKDF ANZFY AUKNY AIZ SKT ZNZ SYKWF PPSHY SKKTY SML AIA FBU RHCGF SPKKY NZTCY SPK ZEL FRCEF AIA FBU ANZLY RYHTY ANZFF MEZ
New Zealand shares slipped as the weakest business confidence in nine years and fears over future profitability weighed on stocks linked to the local economic cycle.
AIA FBU RHCGF AIR FCREY SPKKY NZTCY SPK NZTCF RYM ACKDF FRCEF ANZFY AUKNY AIZ SKT SYKWF AIA PPSHY FBU ANZLY RYHTY SKKTY ANZFF
New Zealand shares edged higher as investors wait for the upcoming round of annual meetings for a clearer steer on company outlooks.
CEN AIR FCREY NZTCF ACKDF ANZFY AUKNY AIZ COENF SKT SYKWF CEN SKKTY AIA FBU SPKKY NZTCY SPK FRCEF COENY AIA FBU ANZLY OHE ANZFF MEZ
New Zealand shares edged higher as strong tourism data boosted prospects for airports and attraction operators. A2 Milk rose for a third day ahead of the reweighting of FTSE indices that it will have a larger presence in.
SKT FBU SYKWF FBU FCREY SKKTY FRCEF
New Zealand shares fell for a third session, taking their weekly decline to 2.3 per cent, as investors cashed in some of August's gains in what was a strong month for the local market. Tourism Holdings and a2 Milk Co declined.
WYN AIR FCREY NZTCF RYM ACKDF ANZFY AUKNY AIZ KMD SKT SYKWF SKKTY KMD SML KTHDY AIA FBU RHCGF SPKKY NZTCY SPK FRCEF AIA FBU THL ANZLY RYHTY OHE ANZFF MEZ
New Zealand shares rose as investors weigh up the prospect of a potential rate cut, spurring demand for stocks with high dividends, in a world economy that remains relatively robust. Sky Network Television, Spark New Zealand and Chorus gained.
KTHDY CEN PGC SPKKY NZTCY SPK NZTCF COENY KMD COENF SKT SYKWF CEN SKKTY KMD
New Zealand shares dipped, led lower by Sky Network Television and Tourism Holdings, but gained over 4 per cent in the month after a busy earnings season.
TME TRMEF AIR FCREY RYM WHGPF ANZFY AIZ FTRRF CGF WHS SKT SYKWF WHOSY TME SKKTY SML FBU RHCGF THO FRCEF FBU THL ANZLY RYHTY ANZFF TDMEY
New Zealand shares surged to a record as the market reopened after yesterday's platform failure. Synlait Milk and A2 Milk Co led the gains.
CEN FBU WBC FCREY ZNRGF WEBNF WBK FRCEF ZEL COENY COENF SKT ZNZ GNE SYKWF WBC FBU CEN SNZ SKKTY GNE GEL SML
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
as of ET